Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.
Alharbi NK, Aljamaan F, Aljami HA, Alenazi MW, Albalawi H, Almasoud A, Alharthi FJ, Azhar EI, Barhoumi T, Bosaeed M, Gilbert SC, Hashem AM. Alharbi NK, et al. Among authors: alenazi mw. Vaccines (Basel). 2022 Aug 17;10(8):1330. doi: 10.3390/vaccines10081330. Vaccines (Basel). 2022. PMID: 36016218 Free PMC article.
Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.
Alharbi NK, Alghnam S, Algaissi A, Albalawi H, Alenazi MW, Albargawi AM, Alharbi AG, Alhazmi A, Al Qarni A, Alfarhan A, Zowawi HM, Alhatmi H, Alghamdi J, Alroqi F, Batarfi K, Arabi YM, Hashem AM, Bosaeed M, Aldibasi O. Alharbi NK, et al. Among authors: alenazi mw. J Infect Public Health. 2021 Jul;14(7):832-838. doi: 10.1016/j.jiph.2021.04.006. Epub 2021 Apr 24. J Infect Public Health. 2021. PMID: 34118732 Free PMC article.
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Bosaeed M, Balkhy HH, Almaziad S, Aljami HA, Alhatmi H, Alanazi H, Alahmadi M, Jawhary A, Alenazi MW, Almasoud A, Alanazi R, Bittaye M, Aboagye J, Albaalharith N, Batawi S, Folegatti P, Ramos Lopez F, Ewer K, Almoaikel K, Aljeraisy M, Alothman A, Gilbert SC, Khalaf Alharbi N. Bosaeed M, et al. Among authors: alenazi mw. Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3. Lancet Microbe. 2022. PMID: 34751259 Free PMC article. Clinical Trial.
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
Alotaibi F, Alharbi NK, Rosen LB, Asiri AY, Assiri AM, Balkhy HH, Al Jeraisy M, Mandourah Y, AlJohani S, Al Harbi S, Jokhdar HAA, Deeb AM, Memish ZA, Jose J, Ghazal S, Al Faraj S, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, AlMutairi BM, Al-Dawood A, Abdullah ML, Barhoumi T, Alenazi MW, Almasood A, Holland SM, Arabi YM; Saudi Critical Care Trials Group. Alotaibi F, et al. Among authors: alenazi mw. Influenza Other Respir Viruses. 2023 Mar 21;17(3):e13116. doi: 10.1111/irv.13116. eCollection 2023 Mar. Influenza Other Respir Viruses. 2023. PMID: 36960162 Free PMC article. Clinical Trial.
Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines.
Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, Alhumaydhi FA, Hashem AM, Bosaeed M, Alsagaby SA. Alharbi NK, et al. Among authors: alenazi mw. Infect Drug Resist. 2022 Jul 29;15:4127-4136. doi: 10.2147/IDR.S362848. eCollection 2022. Infect Drug Resist. 2022. PMID: 35937784 Free PMC article.
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.
Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, Aldubaib M, Almansour A, Temperton NJ, Kupke A, Becker S, Abu-Obaidah A, Alkarar A, Yoon IK, Azhar E, Lambe T, Bayoumi F, Aldowerij A, Ibrahim OH, Gilbert SC, Balkhy HH. Alharbi NK, et al. Among authors: alenazi mw. Sci Rep. 2019 Nov 8;9(1):16292. doi: 10.1038/s41598-019-52730-4. Sci Rep. 2019. PMID: 31705137 Free PMC article.